208 related articles for article (PubMed ID: 34755974)
1. Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review.
Tan AJ; Streicher JL; Merola JF; Noe MH
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755974
[TBL] [Abstract][Full Text] [Related]
2. Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary.
Papp KA; Haraoui B; Kumar D; Marshall JK; Bissonnette R; Bitton A; Bressler B; Gooderham M; Ho V; Jamal S; Pope JE; Steinhart AH; Vinh DC; Wade J
J Rheumatol; 2019 Jul; 46(7):751-754. PubMed ID: 30709945
[TBL] [Abstract][Full Text] [Related]
3. Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.
Goyal A; Goyal K; Merola JF
Am J Clin Dermatol; 2015 Jun; 16(3):179-95. PubMed ID: 25854805
[TBL] [Abstract][Full Text] [Related]
4. Vaccines and use of immunosuppressive and immunomodulatory therapy in a pediatric dermatology clinic-A single institution experience.
Tran J; Trinh DL; Pan AY; Humphrey SR
Pediatr Dermatol; 2023; 40(4):644-646. PubMed ID: 37321854
[TBL] [Abstract][Full Text] [Related]
5. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.
Wine-Lee L; Keller SC; Wilck MB; Gluckman SJ; Van Voorhees AS
J Am Acad Dermatol; 2013 Dec; 69(6):1003-13. PubMed ID: 24075223
[TBL] [Abstract][Full Text] [Related]
6. Vaccines: Considerations for pediatric dermatology patients on immunosuppressive agents.
Munshi MA; Noe MH; Chiu YE; Streicher JL
Pediatr Dermatol; 2021 Sep; 38(5):1040-1046. PubMed ID: 34060143
[TBL] [Abstract][Full Text] [Related]
7. Practical Management of Immunosuppressants in Dermatology.
Leis-Dosil VM; Prats-Caelles I
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):24-34. PubMed ID: 28964393
[TBL] [Abstract][Full Text] [Related]
8. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.
Benchimol EI; Tse F; Carroll MW; deBruyn JC; McNeil SA; Pham-Huy A; Seow CH; Barrett LL; Bessissow T; Carman N; Melmed GY; Vanderkooi OG; Marshall JK; Jones JL
Gastroenterology; 2021 Aug; 161(2):669-680.e0. PubMed ID: 33617891
[TBL] [Abstract][Full Text] [Related]
9. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.
Holcomb ZE; Santillan MR; Morss-Walton PC; Salian P; Her MJ; Giannotti NM; Kimball AB; Porter ML
J Am Acad Dermatol; 2020 Oct; 83(4):1215-1218. PubMed ID: 32622141
[No Abstract] [Full Text] [Related]
10. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions.
Lehman JS; Kalaaji AN
J Am Acad Dermatol; 2010 Nov; 63(5):815-23. PubMed ID: 20643496
[TBL] [Abstract][Full Text] [Related]
11. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy.
Stine JG; Bass M; Ibrahim D; Khokhar OS; Lewis JH
South Med J; 2011 Dec; 104(12):781-8. PubMed ID: 22089354
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and immunosuppressants: An opinion pool of practicing dermatologists of India.
Ray A; Debata I; Agrawal I; Panda M
Dermatol Ther; 2020 Nov; 33(6):e14036. PubMed ID: 32697015
[No Abstract] [Full Text] [Related]
13. [My patient will receive immunosuppressive therapy : which vaccination for each situation ?].
Moschouri E; Bart PA
Rev Med Suisse; 2016 Nov; 12(540):1997-2002. PubMed ID: 28696606
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis.
Gonzalez Santiago TM; Wetter DA; Kalaaji AN; Limper AH; Lehman JS
Int J Dermatol; 2016 Aug; 55(8):823-30. PubMed ID: 27009930
[TBL] [Abstract][Full Text] [Related]
15. Azathioprine: its uses in dermatology.
Chavez-Alvarez S; Herz-Ruelas M; Villarreal-Martinez A; Ocampo-Candiani J; Garza-Garza R; Gomez-Flores M
An Bras Dermatol; 2020; 95(6):731-736. PubMed ID: 33250113
[TBL] [Abstract][Full Text] [Related]
16. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases.
Pileggi GS; Da Mota LMH; Kakehasi AM; De Souza AW; Rocha A; de Melo AKG; da Fonte CAM; Bortoletto C; Brenol CV; Marques CDL; Zaltman C; Borba EF; Reis ER; Freire EAM; Klumb EM; Christopoulos GB; Laurindo IMM; Ballalai I; Da Costa IP; Michelin L; de Azevêdo Valadares LD; Chebli LA; Lacerda M; Toscano MAF; Yazbek MA; De Abreu Vieira RMR; Magalhães R; Kfouri R; Richtmann R; Merenlender SDCS; Valim V; De Assis MR; Kowalski SC; Trevisani VFM
Adv Rheumatol; 2019 Apr; 59(1):17. PubMed ID: 31036077
[TBL] [Abstract][Full Text] [Related]
17. Smallpox vaccination and adverse reactions. Guidance for clinicians.
Cono J; Casey CG; Bell DM;
MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
[TBL] [Abstract][Full Text] [Related]
18. Anticipating and preventing infection in patients treated with immunosuppressive medications for dermatologic indications: a dermatologist's checklist.
Lehman JS; Wetter DA; Davis MD; el-Azhary RA; Gibson LE; Kalaaji AN
J Am Acad Dermatol; 2014 Oct; 71(4):e125-6. PubMed ID: 25219725
[No Abstract] [Full Text] [Related]
19. Efficacy of the vaccination in inflammatory bowel disease.
Carrera E; Manzano R; Garrido E
World J Gastroenterol; 2013 Mar; 19(9):1349-53. PubMed ID: 23538553
[TBL] [Abstract][Full Text] [Related]
20. Immunizations in immunocompromised patients: a guide for dermatologists.
Mohme S; Schmalzing M; Müller CSL; Vogt T; Goebeler M; Stoevesandt J
J Dtsch Dermatol Ges; 2020 Jul; 18(7):699-723. PubMed ID: 32713146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
